Transgenic transchromosomal rodents for making human antibodies

Patent metadata

Field	Value
Publication number	US-9426970-B2
Application number	US-201414339929-A
Country	US
Kind code	B2
Filing date	Jul 24, 2014
Priority date	Nov 30, 2000
Publication date	Aug 30, 2016
Grant date	Aug 30, 2016

Abstract

The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.

First claim

What is claimed is:

1. A method for generating a plurality of B cells expressing human antibody sequences, the method comprising immunizing a transgenic mouse to generate a plurality of B cells expressing human antibody sequences, wherein the transgenic mouse comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome.

2. The method of claim 1 , further comprising isolating the plurality of B cells expressing human antibody sequences from the transgenic mouse.

3. The method of claim 2 , further comprising fusing the plurality of B cells with immortalized cells to form hybridomas.

4. The method of claim 3 , further comprising isolating the human antibody sequences from the hybridomas.

5. The method of claim 4 , wherein the human antibody sequences are purified.

6. The method of claim 1 , further comprising isolating nucleic acid sequences encoding the human antibody sequences from the transgenic mouse.

7. The method of claim 6 , wherein the nucleic acid sequences encoding the human antibody sequences are full length.

8. The method of claim 7 , further comprising expressing the nucleic acid sequences in a transfected cell.

9. The method of claim 1 , wherein the transchromosome comprising a fragment of human chromosome 14 is transchromosome SC20.

10. The method of claim 1 , wherein the transgene is KCo5 transgene.

11. A method for generating a human antibody that binds to a predetermined antigen, the method comprising:
immunizing a transgenic mouse with the predetermined antigen; and
isolating the human antibody from the immunized transgenic mouse,
wherein the transgenic mouse comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome.

12. The method of claim 11 , wherein the human antibody binds to a predetermined antigen with an equilibrium association constant (Ka) of at least 10 10 M −1 .

13. The method of claim 11 , wherein the human antibody is an IgG isotype or an IgA isotype.

14. The method of claim 11 , wherein the human antibody is antigen-specific.

15. A method for generating antigen-specific hybridomas secreting a human antibody, the method comprising:
immunizing a transgenic mouse with a predetermined antigen;
fusing lymphocytes from the transgenic mouse with immortalized cells to form hybridoma cells; and
identifying hybridomas that secrete a human antibody that specifically binds to the predetermined antigen,
wherein the transgenic mouse comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome.

16. A method for generating a human antibody that binds to a predetermined antigen, the method comprising:
immunizing a transgenic mouse with a predetermined antigen;
fusing lymphocytes from the transgenic mouse with immortalized cells to form hybridoma cells; and
screening hybridoma cells formed for the presence of antigen reactive antibodies, wherein the transgenic mouse comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome.

17. The method of claim 16 , wherein the antigen reactive antibodies are secreted from the hybridoma in culture.

Assignees

• Kyowa Hakko Kirin Co Ltd
• Squibb & Sons Llc

Inventors

• Tomizuka Kazuma
• Ishida Isao
• Lonberg Nils
• Halk Edward L

Classifications

• C12N5/0635

  B lymphocytes · CPC title

• A01K2217/30

  Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/2812

  against CD4 · CPC title

• C07K16/18

  against material from animals or humans · CPC title